Attractive Targeted Sugar Bait Trial in Mali
NCT04149119 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2100
Last updated 2021-07-07
Summary
Globally, the female mosquitoes to be effective at transmitting malaria parasites, must have a number of characteristics including: abundance, longevity (individual mosquitoes must survive long enough after feeding on infected blood to allow the parasite time to develop and travel to the mosquito's salivary glands), capacity (each female mosquito must be both susceptible to infection with Plasmodium and able to carry enough malaria parasites in the salivary glands), contact with humans (frequently feed on humans).
Vectors in SSA are often anthropophagic and anthropophilic, and exhibit indoor biting and indoor resting behavior. Highly effective interventions against vectors have been developed and implemented at scale (e.g., indoor Residual Spraying of Insecticides \[IRS\] and Long Lasting Insecticide-treated Nets \[LLINs\]). While these interventions have contributed importantly to the reduction of malaria transmission and disease (68% and 11% respectively), none of them target outdoor-biting g and outdoor-resting mosquitoes. Given the increase in resistance to current generation of insecticides and the behavioral plasticity of vectors that results in continued malaria transmission despite high coverage of LLINs or IRS, there is a need for interventions that can supplement and complement LLINs and IRS by killing mosquitoes outside houses using other biologic mechanisms (e.g., targeting sugar feeding behavior). Finally, insecticides with novel modes of action that may be capable of restoring sensitivity to pyrethroids by killing both pyrethroid resistant and sensitive mosquitoes are required. Attractive Target Sugar Baits (ATSBs) that kill mosquitoes through the ingestion of the toxicant dinotefuran (and possibly by other ingestion toxicants that are effective when ingested) potentially fill the need for outdoor interventions with novel killing effects. This study aims to establish the efficacy and contribution of the ATSBs for controlling malaria transmission where An. gambiae s.l. and An. Funestus are the major vectors for malaria.
Conditions
- Vector Transmission
Interventions
- DEVICE
-
Attractive Target Sugar Baits (ATSB)
Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
Sponsors & Collaborators
-
University Clinical Research Center, Mali
lead OTHER
Principal Investigators
-
Seydou Doumbia, PhD · University Clinical Research Center - USTTB - Mali
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- FACTORIAL
Eligibility
- Min Age
- 5 Years
- Max Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-05-01
- Primary Completion
- 2023-12-31
- Completion
- 2024-06-30
Countries
- Mali
Study Locations
More Related Trials
-
Spatial Repellents for Vector Control
NCT04795648 ·Status: COMPLETED ·Phase: NA
-
Trial to Assess the Efficacy of Malaria Vaccine PfCS 102
NCT01031524 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Malaria Vaccine for Children in Mali
NCT00740090 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
NCT03510481 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
NCT02925403 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Don gu Bougou, Mali
NCT00341783 ·Status: TERMINATED
-
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali
NCT02627456 ·Status: COMPLETED ·Phase: PHASE1
-
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities
NCT06179732 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Finding Trial of R21/Matrix-M in School Children
NCT07074665 ·Status: RECRUITING ·Phase: PHASE2
-
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum
NCT00487916 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
NCT07038837 ·Status: RECRUITING ·Phase: PHASE4
-
Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali
NCT00863408 ·Status: COMPLETED
-
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children
NCT00307021 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali
NCT06413108 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Experimental PfSPZ Vaccine in Adults Without Malaria
NCT01441167 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
NCT02015091 ·Status: COMPLETED ·Phase: PHASE1
-
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
NCT06268691 ·Status: COMPLETED ·Phase: NA
-
Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
NCT03917654 ·Status: COMPLETED ·Phase: PHASE2
-
Malaria Vaccine Pilot Evaluation
NCT03806465 ·Status: COMPLETED
-
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
NCT07147400 ·Status: RECRUITING ·Phase: PHASE2
-
Experimental Vaccine for Malaria in Adults in Mali
NCT00343005 ·Status: COMPLETED ·Phase: PHASE1
-
R21/Matrix-M in African Children Against Clinical Malaria
NCT04704830 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
NCT03641339 ·Status: COMPLETED ·Phase: NA
-
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
NCT03952650 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
NCT03896724 ·Status: COMPLETED ·Phase: PHASE1/PHASE2